---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-010161"
form_type: "8-K"
ticker: null
cik: "0001651407"
company_name: "Checkpoint Therapeutics, Inc."
filed_at: "2024-02-02T23:59:59+00:00"
generated_at: "2026-06-06T09:57:07.296717+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Checkpoint Therapeutics fails Nasdaq board independence rule after director resignation

## Summary
- Scott Boilen resigned from Board effective Jan 31, 2024; company no longer has majority independent directors as required by Nasdaq Rule 5605(b)(1).
- Nasdaq confirmed non-compliance via letter on Feb 2, 2024; no immediate impact on listing or trading of CKPT common stock.
- Company has cure period until earlier of next annual shareholders' meeting or Jan 31, 2025; if annual meeting before July 29, 2024, compliance due July 29, 2024.
- Board intends to regain compliance with Board Independence Rule before cure period expires.

## SEC filing metadata
- accession: 0001104659-24-010161
- form_type: 8-K
- cik: 0001651407
- company_name: Checkpoint Therapeutics, Inc.
- filed_at: 2024-02-02T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651407/000110465924010161/0001104659-24-010161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651407/000110465924010161/tm245111d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-010161
- JSON: https://secwatch.observer/filing/0001104659-24-010161.json
- Plain text: https://secwatch.observer/filing/0001104659-24-010161.txt

## Key facts
- Listing & Compliance Notices
  Checkpoint Therapeutics, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605(b)(1), 5605(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: board independence
  - Rules: 5605(b)(1), 5605(a)(2)
  source text: February 2, 2024, the Company received a letter from Nasdaq confirming that the Company was no longer in compliance with the Board Independence Rule. The Company’s non-compliance with the Board Independence Rule does not have an immediate effect on the listing or trading of the Company’s common stock, which continues to be listed and traded on the Nasdaq Capital Market under the symbol “CKPT.” In accordance with Rule 5605(b)(1)(A) of the Nasdaq listing standards, the Company has until the earlier of its next annual shareholders’ meeting or January 31, 2025, to regain compliance; provided, howe
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651407/000110465924010161/0001104659-24-010161-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.